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Abstract
Recent progress in the Nerve Growth Factor (NGF) research has shown that this factor acts not only outside its
classical domain of the peripheral and central nervous system, but also on non-neuronal and cancer cells. This latter
observation has led to divergent hypothesis about the role of NGF, its specific distribution pattern within the tissues
and its implication in induction as well as progression of carcinogenesis. Moreover, other recent studies have
shown that NGF has direct clinical relevance in certain human brain neuron degeneration and a number of human
ocular disorders. These studies, by suggesting that NGF is involved in a plethora of physiological function in health
and disease, warrant further investigation regarding the true role of NGF in carcinogenesis. Based on our long-
lasting experience in the physiopathology of NGF, we aimed to review previous and recent in vivo and in vitro NGF
studies on tumor cell induction, progression and arrest. Overall, these studies indicate that the only presence of
NGF is unable to generate cell carcinogenesis, both in normal neuronal and non-neuronal cells/tissues. However, it
cannot be excluded the possibility that the co-expression of NGF and pro-carcinogenic molecules might open to
different consequence. Whether NGF plays a direct or an indirect role in cell proliferation during carcinogenesis
remains to demonstrate.
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Background
The Nerve Growth Factor (NGF) was discovered by R.
Levi-Montalcini nearly 60 years ago after the transplant-
ation of a malignant mouse sarcoma into the body wall
of a 3-day-old chick embryo [1, 2]. Subsequent studies
revealed that the purified murine NGF (adult submaxil-
lary gland) stimulates morphological differentiation, reg-
ulates neuronal gene expression (through interaction
with specific cellular receptors) and plays a critical role
in mature neurons for acting directly on peripheral sen-
sory and sympathetic neurons and for maintaining their
function and phenotype [3, 4]. Structural, biochemical
and molecular studies indicate that a trophic interaction
failure between target cells and their innervations might
result in nerve dysfunction and neuronal degeneration
[5, 6]. These findings led to the hypothesis that purified
NGF might be a useful tool to prevent and/or protect
peripheral nerves from degeneration, as observed in
Diabetes [7]. The history of NGF in clinical trials of
Diabetes is exemplary with respect to the potentiality of
NGF in the care of peripheral neuropathies [8, 9]. More-
over, studies carried out in animal models and humans
demonstrated that NGF can promote survival, differenti-
ation and functional activity of peripheral sensory and
sympathetic nerve cells [8]. Diabetes is a metabolism
disorder characterized by degeneration of peripheral
neuron/fibers and altered local levels of NGF/NGF re-
ceptors and deregulation of NGF signal pathway [7]. In
experimental models of diabetic neuropathies, NGF ad-
ministration reversed the neurodegenerative signs and
normalized the activity of neurons belonging to the
Peripheral Nervous System [6]. The results of the above
reported clinical trials were partially confirmed by suc-
ceeding clinical trials and thereafter the human studies
were closed [8]. The reason of dissimilar outcomes be-
tween first and second clinical trials is still not clear. A
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possible hypothesis might encompass a different bio-
logical preparation and/or composition of NGF formula-
tion, the not-homogeneous study populations (in terms
of age, onset and severity as well as clinical history of
the neuropathy), the different selection of the placebo
patient group and finally the occurrence of undesirable
side effects [10]. The most reasonable explanation for
this clinical study failure and the interruption of NGF
investigations in diabetic neuropathies could be associ-
ated with the necessity to use low NGF dosage (for side
effects) in comparison with those of animal studies [10].
The Authors concluded that a simply approach to inves-
tigate the role of NGF in human peripheral neuropathy
could be the use of molecules with the ability to stimu-
late both synthesis and release of NGF at the proximity
of damaged tissue [10]. This aspect would imply the pos-
sibility to induce endogenous NGF upregulation, with
no NGF-related side effects [10]. Subsequently, studies
revaled that NGF exerts a critical protective action on
specific brain cells and particularly on the basal fore-
brain derived neurons undergoing degeneration in
Alzheimer disease (AD) [5] and a variety of non-
neuronal and neoplastic cells [1]. Moreover, these
studies revealed that the protective NGF role in human
target cells might occur also outside the classical ner-
vous system domain, as observed in the treatment of
corneal ulcers [11], Glaucoma [12], Maculopathy [13],
Retinitis Pigmentosa [14] and AD [15, 16]. These studies
would suggest the use of NGF in the near future for the
treatment of human pathologies with damaging of
NGF-responsive cells.
By the way, the presence of NGF and NGF-receptors
in cancer cells raised the question as whether NGF is in-
volved in promoting cell proliferation and eventually
cancer cell survival [17]. To gain further information on
this aspect, our aim was to summarize and review our
and other literature available finding on NGF in cancer
cell survival, proliferation and cell arrest, within and out-
side nervous system, both at baseline and following ex-
posure to purified NGF.
NGF as pro-survival molecule
NGF and NGF-receptors (trkANGFR and p75NTR) play a
critical role in proliferation, differentiation and survival of
developing peripheral and central nervous system neu-
rons, influencing their activity in many ways [2, 18–20].
Focused in vitro studies showed that rat sympathetic
nerve (Fig. 1a) and brain cells (subvetricular zone) exhib-
ited both differentiation and neuritis outgrowth but no
cell proliferation when cultured in the presence of purified
NGF (Fig. 1b, arrows). The absence of cell proliferation
upon NGF exposure is consistent with several studies
showing that systemic NGF administration is associated
with an increased activity of NGF at both peripheral and
central target neurons [2, 4, 6, 19]. An interesting protect-
ive role of NGF is the ability to guarantee the physiological
activity inside the tissue microenvironment, by preserving
the tissue/organ functional activity, as observed in the
protection of corneal nerve cells and in the regulation of
homeostasis within nervous, immune and endocrine sys-
tems [21]. In vivo and in vitro studies confirmed that NGF
plays a marked role in the (i) differentiation and (ii) sur-
vival of developing neurons belonging to peripheral and
central nervous system as well as in the (iii) protection of
degenerating young and adult neurons [2]. Also, NGF has
been reported to promote the regulation of neurotrans-
mitter expression/release, facilitate axon guidance/synapse
formation and modulate synaptic activity/function (for
further details see [4]). Overall, these findings are consist-
ent with other studies showing that systemic NGF admin-
istration is associated with an increased biological activity
of NGF-target cells and not related with the induction of
cancer cell proliferation [4, 17, 22, 23].
NGF and uncontrolled cell proliferation
The question about NGF role in tumor induction/
progression has been investigated in different in vivo and
in vitro experimental approaches. Evidences that some
tumor tissues and their isolated tumor cells can express
NGF-receptors and/or store NGF protein suggested the
Fig. 1 Photographic illustration of untreated (baseline, left panels)
and treated (NGF exposure, right panels) cultured cells. As shown by
phase contrast acquisition, exposure to 20 ng/ml NGF for seven
consecutive days promoted differentiation and neuritis outgrowth
(right panels) rather than cell proliferation of sympathetic (b), tumor
PC-12 (d) and beta pancreatic (f) cell lines, as compared to untreated
ones (left panels). Magnifications: x400. a-d, phase contrast; e-f,
light microscopy
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hypothesis that NGF might be involved in tumor cell in-
duction and/or progression [24–27]. A consistent number
of experimental studies have demonstrated the expression
of NGF and NGF-receptors in neural crest-derived cells as
well as in tumor cell lines from neuroblastoma, lymphoma,
glioma, medulloblastoma adrenal tumors and melanoma,
suggesting that NGF administration on trkANGFR-bearing
cells could lead to cell differentiation and improved prog-
nosis [28–30]. On the contrary, NGF by itself is unable to
induce/generate cancer cell proliferation from normal
tissues/cells or sustain cancer cell progression [31]. There-
fore, the hypothesis that NGF administration can promote
uncontrolled cell proliferation (leading to cancer develop-
ment) seems to have weak experimental evidence. It is
noterworth to highlight that consistent NGF amounts are
physiologically produced, stored and secreted by several
cells/tissues as well as released into mammalian blood-
stream (including humans) [2, 32, 33]. Several tissues pro-
duce and release NGF under physiological and neoplastic
conditions (prostate included) and the locally-released NGF
can exert both differentiatial and pro-survival activities on
neuronal and non-neuronal tumor cells, depending on type
of tumor and expression of trkANGFR and/or p75NTR recep-
tors [34, 35]. Cell proliferation, survival and differentiation
are under control of different signal transduction systems.
The Mitogen-activated protein kinases (MAPKs) and the
Ras (Ras/Raf/MEK/ERK) cascades represent key molecules
for trk signaling and modulate all the hallmarks of cancer
cells (survival, migration and invasion). Thereafter, specific
inhibitors targeting these pathways represent crucial ap-
proaches to counteract tumor developing/progression, as
observed for the inhibitor of MEK1 (Cobimetinib) allowing
the differentiation and apoptosis in neuroblastoma cells
and the kinase inhibitor D11 mediating apoptosis of cancer
cells resistant to chemotherapy [36, 37]. On the other side,
growth factors modulate several aspects of cell functions
inside different microenvironments. The presence of a
stem-like phenotype in tumors was confirmed by the iden-
tification of a small portion of cell population with the char-
acteristics of stem cells inside tumor tissues [38]. Because
of the self-renewing capacity and the multi-directional
differentiative potential, these cancer stem cells can repre-
sent source of tumor cells with different degree of differen-
tiation inside the tissue. Contrasting data encompass the
relationship between CD133/nestin (markers of neural stem
cells and of cancer stem cells in neurogenic tumors) and
prognosis of patients with glioma [38]. Therefore, it is un-
doubted the great value of understanding the role of growth
factors, and merely NGF and NGF-receptors, in tumor
developing/progression, as well as the development of
tumor growth factor targeted approaches.
Merely to NGF interaction in tumor cells, Zhu and co-
workers highlighted that the NGF–trkANGFR interaction
influences growth and spread of pancreatic cancer cells,
Zhang and coworkers highlighted the prognostic value
of NGF-receptors while Missale and coworkers showed
the NGF-receptor overexpression associated with a good
prognosis [39–41]. Farina and coworkers described a dif-
ferent trkANGFR isoform (trkA III, the result of an alter-
native splicing) able to induce an aberrant and
aggressive proliferation in neuroblastoma cells [42]. In a
very recent study, Ruggeri and co-workers highlighted
that NGF binding to trkANGFR and TRAIL (TNF-related
apoptotis-inducing ligand) might suppress neuroproli-
feration in neuroblastoma by inducing apoptosis [43].
These findings suggest that the high trkANGFR expres-
sion can provide a more favorable survival prognosis in
breast cancer and neuroblastoma, although the under-
lined mechanisms and the direct relationships between
trkANGFR and p75NTR remain poorly understood and/or
explored. In addition, it was reported that the selective
p75NTR expression by prostate tumor cells could induce
cell cycle arrest and apoptosis, both crucial steps for po-
tential anti-tumoral therapy [34, 35]. Studies reported by
Ødegaard and coworkers showed a reduced expression/
activation of trkANGFR in effusions as compared with
solid ovarian carcinoma and that trkANGFR expression
appeared to be independent of cell cycle progression,
suggesting the phosphorylated trkANGFR form (known
as p-trkANGFR) as a potential marker of prognostic
value [30, 39].
NGF and tumor cell inhibition
Over the last three decades, a consistent number of pub-
lished studies have shown that NGF can promote cell
differentiation and arrest tumor progression, as observed
in primary and cell line tumor cells [31, 44–50]. Particu-
larly, several in vitro experiments have shown that NGF
is capable of retarding growth and inducing persistent
differentiation of neurogenic tumor cell lines [51]. As
shown, PC-12 tumor cells proliferate under baseline
conditions (Fig. 1c) and start to differentiate and pro-
duce neuritis after NGF exposure over few consecutive
days (see arrows in Fig. 1d). Likewise, cultured beta-
tumor pancreatic cells proliferate in the absence (Fig. 1e)
and stop to proliferate after the addition of NGF to the
culture medium (arrows in Fig. 1f ). Studies on animal
models demonstrated that NGF is able to (i) induce the
persistent reduction of the number of Ethylnitrosourea
(ENU) -induced neurinomas and (ii) increase the sur-
vival time of rats after intracerebral implantation of the
F98 anaplastic glioma cells [52]. Either in tranplacental
or postnatal ENU-exposure, NGF treatment caused a re-
duction of the number of ENU-induced neuromas in
rats [52, 53]. As observed after topical administration,
exogenous NGF can arrest tumor cell proliferation in
human ocular glioma, prompting to the hypothesis of an
inhibitory rather than promoting NGF effect on cancer
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cell (stimulation and tumor progression) [46, 54, 55].
These observations seem to support the hypothesis that
the predominant expression of trkANGFR might facilitate
cell differentiation while the p75NTR expression in the
absence of trkANGFR might facilitate cell proliferation
[56]. Regarding the hypothesis of a favorable link be-
tween expression of NGF/NGF-receptors and tumor cell
proliferation, it should be taken into consideration that
the presence and/or release of “well established” pro-
oncogenic molecules might precede the presence of
NGF. These studies indicated that (i.) the NGF treat-
ment can trigger the development of a more differenti-
ated cell phenotype and as result cause the reduction or
complete cessation of tumor growth and more interest-
ing (ii.) the effects of NGF can be persistent, all together
supporting the hypothesis that NGF can reverse trans-
formed properties of susceptible tumor cell progression.
NGF, microenvironment and immunocompetent cell
The interaction between immune and tumor cells is cru-
cial for tumor growth and progression, as highlighted by
several old and recent studies in both animal and human
models [47–49]. Although tumors have their own “cell
shelter mechanisms” (immune escape, resistance to
apoptosis and cell survival), a host-mediated immune re-
sponse against tumors can occur and consequently two
different models have been proposed. The “immunosur-
veillance model” suggests that tumor cells (by expressing
proper surface antigens) are regarded as “non-self” and
thereafter eliminated by the immune system, although
some unknown mechanisms counteract with this physio-
logical protective route [48]. According to the “danger
model”, the professional sentinels of tissue damage
(Antigen Presenting Cells, APCs; dendritic cells and
activated macrophages), B and T cells are activated/
stimulated by risk-signals but do not recognize cancer
cells as dangerous, and thereafter the appropriate T cell
response to tumors does not occur [48].
In both cases, the composition of tissue microenviron-
ment might play a crucial role. An accurate analysis of
the microenvironment in a variety of solid tumor sec-
tions has revealed the presence of a T cell–infiltrated
phenotype, macrophages, neutrophils, recruited mast
cells and infiltrating eosinophils [49]. Such a micro-
environment might play a crucial role in tumor
launch/progression, including the local sustaining and
development of tumor-associated angiogenesis [49].
Microenvironment is strictly linked to the genetic
background and the interplay between infiltrating/
resident immune (APCs, NK cells, B-T lymphocytes
as well as mast cells and eosinophils) and epithelial/
stromal cells. The release of different pro/anti-inflammatory
and pro/anti-angiogenic factors (cytokines, chemokines,
growth/fibrotic/angiogenic factors and tissue remodeling
enzymes) might significantly influence and/or modulate
local immune response and angiogenesis [48, 50, 57–59].
Studies published during the early ’90s revealed that
NGF plays a critical role in the mechanisms of neuro-
immune-endocrine homeostasis [60]. The first study
prospecting this aspect reported that NGF stimulates the
survival of Mast Cells (MCs) and modulates the specific
function of MCs and lymphocytes, providing substantial
evidences that NGF could actively contribute to both in-
nate and adaptive immune responses [61, 62]. Further
studies into this field led to the discovery that macro-
phages, granulocytes, T and B subtypes, NK cells and eo-
sinophils are not only NGF-target cells (survival and
function) but also synthesize, store and release consist-
ent amounts of NGF [63–68]. The presence of physio-
logical amounts sustains the crucial NGF role in both
innate and adaptive immune cells. The tumor micro-
environment might release high amount of NGF and re-
spond to extracellular NGF in autocrine/paracrine
fashion. NGF immunoreactivity has been observed in
several tumor tissues and cells [69, 70]. The observation
that NGF is a soluble mediator, either released into or
produced by the tumor microenvironment, and the fact
that NGF is able to act on certain immune-cell activities,
would suggest a possible control of cell proliferation to-
wards resistance to cancer survival [71, 72]. It is note-
worthy to highlight that some soluble mediators can
exert a dual-faced action, implying that immune cells
can have both active and/or bystander effects [71, 72].
Conclusions
NGF is released in the bloodstream of mammalians
(human included) and is critically involved in the protec-
tion of several neuronal and non-neuronal cell types, in-
cluding healthy and tumor cells [2, 73]. The presence of
NGF protein and the expression of NGF-receptors in
cancer cells have produced a number of divergent hy-
potheses as whether NGF is directly involved in cancer
cell proliferation and differentiation. Since the great het-
erogeneity of cancer cells (stage of differentiation, malig-
nancy and production/release of different ligands) may
represent a signal for promoting cell neoplasy, the iden-
tification of NGF – cancer cell interaction might clearly
establish whether this factor acts as a first signal. So far,
these aspects have not been taken into consideration or
not yet been sufficiently investigated. The observation
that NGF-exposed naive cells do not generate cancer cell
phenotypes argues against a primary role of NGF in pro-
moting cancer cell generation. Indeed, the experimental
evidence that NGF exposure induces differentiation ra-
ther than proliferation in cancer cell line (pheochromo-
cytoma, glioma, neuroblastoma and pancreatic beta
cells) argues against the pro-cancer role of NGF
(Fig. 2ab). The observations that (i) the murine salivary
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glands, by producing and releasing great amounts of
NGF (Fig. 2c), do not induce local/systemic tumor cell
development; (ii) the exogenous single or repeated
(systemically or intracerebroventricular) administration
of NGF is unable to generate local tumor development
[7, 8, 11–13]; (iii) the large amount of NGF produced by
Sarcomas’ 180 and 137 were not able to generate tumor
cell proliferation when transplanted into chick and
mouse embryos, but on the contrary stimulated nerve
cell differentiation and neuritis outgrowth [17, 22] and
(iv) the evidence that the addition of purified NGF to
tumor cell lines (rat PC-12) [45] or human epindenoma
and glioma [31] can arrests tumor cell proliferation and
stimulate cell differentiation, support the hypothesis that
the NGF administration by itself is not sufficient to gen-
erate/promote cell tumorigenesis, including cancer cell
proliferation and tumor development/progression. Like-
wise, recent studies indicate that topical ocular NGF
administration reduces glioma in vivo and the progres-
sion of pediatric optic glioma [46, 54, 55]. The possibility
that NGF in concert with other pro-cancer biological
mediators might play a role in cell survival cannot be ex-
cluded, but this effect and the underlined mechanisms
need to be identified. In this contest, it is worth men-
tioning that NGF is produced at high concentrations in
human prostate, under physiological and neoplasy con-
ditions [35]. Cumulatively, the above reported in vitro
and in vivo observations sustain the hypothesis that
persistent NGF activity can suppresses cancer cell prolif-
eration, even if these neoplastic cells express both NGF-
receptors and respond to NGF action.
This hypothesis is consistent with a number of previous
and recent studies showing that NGF promote differenti-
ation of cultured tumor cells and that single/repeated in
vivo subcutaneously [17, 22, 72, 73], intracerebrally [5,
74], intranasally [75], topically [11–13, 76–79] and orally
[80] NGF administered or even endogenously-induced/
released NGF [73] do not cause uncontrolled cell prolifer-
ation nor lead to cancer cell generation. Although the
available observations are consistent with such hypothesis,
further studies might be necessary to determine whether a
given population of tumor cells is entirely NGF-
responsive or contains a proportion of unresponsive cells.
Finally, in line with the observation that repeated NGF
administration in human pathologies do not promote
cell neoplasy [17, 46, 54, 55], our working hypothesis
and future investigation are to pursue studies on bio-
chemical and molecular signals and factors, as well as to
develop novel in vitro and in vivo strategies to confirm
or debate the anti-tumoral properties of NGF.
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Fig. 2 High levels of exogenous and/or endogenous NGF in tissues
without cell proliferation. Illustrations of exogenous NGF-induced
trkANGFR expression (a-b) and endogenous NGF expression (c).
a Representative brain section from a young rat treated with 1 μg
purified NGF into the third brain ventricle. Note the trkANGFR
immunreactivity in the dentate gyrus of the hippocampus (arrows).
The absence of any sign of cell proliferation within and nearby the
hippocampal tissues is clearly visible. b Representative cutaneous
tissue section from a mouse exposed to subcutaneous administration of
10 μg purified NGF. An increased trkANGFR immunoreactivity is visible
(arrows) in the dermal tissue having no cell proliferation. c Representative
submaxillary gland sections from a 10-week-old male-mouse probed with
anti-NGF antibody (arrows). Despite the massive NGF immunoreactivity in
murine salivary gland (tubular cells; see arrows), no cell proliferation nor
cell neoplasy characterized the gland tissue. Magnifications: ab, x100;
c, x400, light microscopy
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